Since it has been proven that some AML blast cells display high levels of BCL-2 protein, mainly amongst chemotherapy-resistant patients [46,47,48,49], antiapoptotic proteins are seen as a promising therapeutic target. The gene discussed is BCL2; the disease is acute myeloid leukemia.